Loading
Life sciences · Journal article
Angewandte Chemie · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Cancer remains a major global health threat. Targeted protein degradation (TPD) has revolutionized the modulation of protein function in therapeutic development. Nevertheless, the design of current TPD agents continues to face challenges, including hook effects and, more critically, the frequent lack of spatial and temporal precision required for in vivo applications. Herein, we report a photoactivatable targeted degradation (PATD) strategy and describe the iterative optimization of compound 9, the first two‐photon‐excited BRD4 photodegrader, achieved through molecular engineering of the photosensitizer core, auxiliary ligands, and linkers. Notably, BRD4 degradation downregulates GPX4 transcription, promoting lipid peroxidation and thereby inducing ferro‐aging, while simultaneously triggering chemo‐aging via histone H3 cleavage, which leads to DNA damage and cell cycle arrest. This dual‐aging mechanism accelerates tumor cell senescence, enabling synergistic seno‐immunotherapy. Beyond conventional photosensitizers that primarily elicit immunogenic cell death (ICD) alone, complex 9 integrates senescence‐driven immunity with ICD‐mediated antitumor immunity. This combined immunostimulatory strategy elicits robust systemic antitumor responses and achieves amplified therapeutic efficacy in patient‐derived organoids (PDOs), presenting a new paradigm for precision targeted protein degradation in therapy‐resistant tumors.